AVTR Earnings Prediction
The chart below shows how AVTR performed 10 days before and after its earnings report, based on data from the past quarters. Typically, AVTR sees a -0.15% change in stock price 10 days leading up to the earnings, and a +0.17% change 10 days following the report. On the earnings day itself, the stock moves by -1.26%. This data can give you a slight idea of what to expect for the next quarter's release.
AVTR Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
1.69B
-2.10%
-1.62%
Gross Margin
33.37%
0.79%
1.37%
Operating Margin
11.35%
6.67%
56.12%
Net Margin
29.67%
418.71%
780.42%
EPS
0.73
421.43%
812.50%
No Data Available
AVTR Earnings Analysis
Avantor Inc Corporation (AVTR.N) Earnings Conference Call
Positive
Bioprocessing Organic Growth: High single-digit organic growth in bioprocessing for Q4, marking the fourth consecutive quarter of outperformance.
EBITDA Margin Expansion: Adjusted EBITDA margin expanded to 18.2%, the highest level in over a year, driven by improved mix and cost transformation initiatives.
Earnings Per Share Growth: Adjusted earnings per share increased to $0.27 in Q4, reflecting a 4% sequential and 8% year-over-year growth.
Free Cash Flow Performance: Generated $222 million in free cash flow for Q4, contributing to a total of $768 million for the year, representing over 110% free cash flow conversion.
Debt Reduction Achievement: Paid down $1.3 billion in debt during 2024, reducing net leverage to 3.2 times adjusted EBITDA, a significant improvement from nearly 4 times at the start of the year.
Negative
Fourth Quarter Revenue Impact: Fourth quarter reported revenue was $1.69 billion, reflecting a $40 million impact from the divestiture of the clinical services business, resulting in only 1% organic growth.
Revenue Decline Analysis: For the full year 2024, reported revenue was $6.78 billion, representing a 2% organic revenue decline versus prior year, aligning with the low end of original guidance.
Revenue Decline Overview: Laboratory Solutions revenue for Q4 was $1.13 billion, a decline of 1% versus prior year on an organic basis, and for the full year, it was $4.61 billion, a 2% decline versus 2023.
Adjusted Gross Profit Analysis: Adjusted gross profit for the year was $2.29 billion, with a 33.8% adjusted gross margin, indicating flat performance compared to the previous year and impacted by inflation and negative fixed cost leverage.
Revenue Decline Forecast: The guidance for 2025 indicates a reported revenue decline of negative 3% to negative 1%, primarily due to a 2% headwind from the clinical services divestiture and another 2% from foreign exchange.
AVTR FAQs
How does AVTR typically perform around its earnings report dates?
Is Avantor Inc (AVTR) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
AVTR Earning Call Sentiment
Avantor, Inc. (NYSE:AVTR) Q4 2024 Earnings Call Transcript
AVTR.N
-4.24%Positive
The earnings call reveals strong financial metrics, with a significant debt reduction, increased free cash flow, and improved margins. Despite a slight organic revenue decline, the company exceeded free cash flow guidance and maintained solid EPS growth. The Q&A session showed confidence in bioprocessing growth and cost savings. While some uncertainties exist, such as macro environment noise and policy risks, the overall sentiment is positive due to strong financial performance and optimistic guidance.
